Latham-Led Actavis Pays $25B For Icahn-Backed Forest Labs
Generic-drug maker Actavis PLC said Tuesday it would swallow Forest Laboratories Inc. in a cash-and-stock deal worth $25 billion that delivers a major win for activist investor Carl Icahn, one of...To view the full article, register now.
Already a subscriber? Click here to view full article